Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $40 | $36 | $30 | $100 |
| Short-Term Investments | $140 | $91 | $98 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $2 | $4 | $1 |
| Total Curr. Assets | $182 | $130 | $132 | $100 |
| Property Plant & Equip (Net) | $8 | $8 | $7 | $6 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $5 | $0 | $42 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $1 | $0 | $0 |
| Total NC Assets | $15 | $9 | $49 | $6 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $197 | $138 | $181 | $107 |
| Liabilities | – | – | – | – |
| Payables | $1 | $5 | $1 | $1 |
| Short-Term Debt | $1 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $15 | $7 | $5 | $1 |
| Total Curr. Liab. | $17 | $13 | $7 | $3 |
| LT Debt | $3 | $4 | $4 | $5 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $123 |
| Total NC Liab. | $3 | $4 | $4 | $127 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $3 | $5 | $5 | $6 |
| Total Liabilities | $20 | $17 | $11 | $130 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$197 | -$116 | -$56 | -$25 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $373 | $238 | $227 | $1 |
| Total Equity | $177 | $121 | $170 | -$24 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $197 | $138 | $181 | $107 |
| Net Debt | -$36 | -$31 | -$25 | -$94 |